BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody


BiondVax Pharmaceuticals Ltd BVXV has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany. 

  • The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.
  • VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs). 
  • These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.
  • The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.
  • The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.
  • BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.
  • The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.
  • Price Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!